Generated by AI
Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners. Natera’s tests are used to support areas such as reproductive health, cancer residual disease monitoring, recurrence surveillance, and organ transplant management. Headquartered in Austin, Texas, Natera plays an important role in the growing precision medicine market by providing non-invasive diagnostic tools that help inform clinical decision-making across multiple medical specialties.
Website13011 McCallen Pass
Austin, TX, 78753
United States
The latest articles about NTRA.
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Investors talking about NTRA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.